Nimbus Therapeutics, Lilly Enter Alliance for Therapeutics for Metabolic Diseases

Nimbus Therapeutics has entered a collaboration and licensing agreement with Eli Lilly for potential therapeutics for metabolic diseases with a potential value of $496 million. The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK for the potential treatment of metabolic diseases. AMPK (AMP-activated protein kinase) is considered a high-value target in this indication due to its role in glucose, lipid metabolism, and inflammation. The companies will work to identify isoform-selective, small molecule activators of AMPK heterotrimers, believed to improve glucose and lipid homeostasis while mitigating safety concerns. Nimbus will apply its computational drug discovery engine to develop isoform-selective small molecule AMPK activators applicable in a broad range of metabolic diseases, leveraging Lilly

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!